10-Minute POC Test Detects and Differentiates Bacterial from Viral Respiratory Infection

Acute respiratory infections, which present symptoms such as a sore throat, cough, and runny nose, are the leading cause of doctor appointments and antibiotic prescriptions. However, diagnosing these conditions can be challenging due to the similar symptoms presented by bacterial and viral infections. Despite the fact that the majority of these infections are viral and do not necessitate antibiotics, they are prescribed in almost 58% of cases, when they're only necessary in about 11%. This overprescription of antibiotics significantly contributes to the rising global threat of antimicrobial-resistant (AMR) bacterial strains. Now, a quick fingerstick blood test capable of distinguishing between viral and bacterial acute respiratory infections within 10 minutes can help doctors apply antibiotics where they're truly needed, thereby combating antibiotic resistance.

The inability to easily distinguish between viral and bacterial infections due to similar symptoms, along with lengthy laboratory test results, is the primary reason for antibiotic misuse. This diagnostic uncertainty, combined with doctors' fear of overlooking bacterial infections and patients' expectations of receiving a prescription, often results in unnecessary antibiotic use. The FebriDx rapid, point-of-care test from Lumos Diagnostics (Melbourne, Australia) assists in diagnosing bacterial acute respiratory infections and differentiating them from non-bacterial causes in patients in urgent or emergency care settings. FebriDx is intended for use along with other clinical and laboratory findings to assess patients with acute respiratory infections.

Determining whether a patient has a viral or bacterial infection could greatly decrease unnecessary antibiotic prescriptions, curb the spread of antibiotic-resistant bacteria, and guide medical practitioners on when to start treatment. The use of a rapid screening test like FebriDx during a patient's visit can help ensure appropriate patient management and streamline practice workflow. The results from FebriDx are available within 10 minutes, enabling the clinician to provide a timely and targeted treatment plan during the initial consultation. Lumos has obtained approval from the US Food and Drug Administration (FDA) to market FebriDx in the United States. The test is also registered in the UK, Europe, Canada, UAE, Brazil, Turkey, Pakistan, Singapore, Malaysia, and Australia.

"We are delighted to finally secure clearance to market our FebriDx rapid, point–of–care test in the US as we continue to believe it has an important role to play in antibiotic stewardship," said Doug Ward, CEO of Lumos Diagnostics.

Related Links:
Lumos Diagnostics

Visit expo >

Platinum Member

COVID-19 Rapid Test

OSOM COVID-19 Antigen Rapid Test

Magnetic Bead Separation Modules
MAG and HEATMAG

Anti-Cyclic Citrullinated Peptide Test

GPP-100 Anti-CCP Kit

New

Gold Member

Plasma Control

Plasma Control Level 1